** Shares of Proteomics International Labs rise as much as 8.4% to A$0.71

** The medical technology co says its PromarkerEso blood test for esophageal adenocarcinoma shows 94% accuracy in clinical validation study

** Co says esophageal adenocarcinoma, a cancer arising in the food pipe, is among the leading cause of cancer-related deaths, with a 5-year survival rate of 20%, due to late diagnosis

** Says improved surveillance of at-risk patients using PromarkerEso could enable earlier diagnosis and significantly improve health outcomes

** Stock has fallen 26.8% this year, as of last close

(Reporting by Sherin Sunny in Bengaluru)

((Sherin.Sunny@thomsonreuters.com))